Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.oraloncology.2007.09.005
DC FieldValue
dc.titleProspective phase II trial of concomitant boost radiotherapy for stage II nasopharyngeal carcinoma
dc.contributor.authorLu, J.J.
dc.contributor.authorShakespeare, T.P.
dc.contributor.authorZhang, Q.
dc.contributor.authorLee, K.M.
dc.contributor.authorKong, L.
dc.contributor.authorLoh, K.S.
dc.contributor.authorLuke, Tan K.S.
dc.date.accessioned2011-09-19T07:39:32Z
dc.date.available2011-09-19T07:39:32Z
dc.date.issued2008
dc.identifier.citationLu, J.J., Shakespeare, T.P., Zhang, Q., Lee, K.M., Kong, L., Loh, K.S., Luke, Tan K.S. (2008). Prospective phase II trial of concomitant boost radiotherapy for stage II nasopharyngeal carcinoma. Oral Oncology 44 (7) : 703-709. ScholarBank@NUS Repository. https://doi.org/10.1016/j.oraloncology.2007.09.005
dc.identifier.issn13688375
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/26290
dc.description.abstractStage II nasopharyngeal carcinoma (NPC) treated with conventionally fractionated radiotherapy results in suboptimal outcome. This report aims to document the outcome of Stage II NPC patients treated with external beam radiotherapy delivered using an accelerated concomitant boost (C-Boost) schedule. Forty-seven 1997 AJCC Stage II NPC patients were enrolled and analyzed in this prospective phase II clinical trial. The primary tumor and clinically involved nodes received a total dose of 72 Gy in 42 fractions. C-Boost for gross disease consisted of 18 Gy in 12 fractions commencing on day 19, and delivered at least 6 h after the first dose. Patients were assessed for response, survival and toxicity. With a median follow-up of 30 months, 4 patients developed local recurrence only, 2 had persistent neck nodal disease or recurrence, and 1 with both locoregional recurrences. Distant metastases were seen in 5 patients, with or without locoregional recurrence. A total of 5 patients succumbed from nasopharyngeal cancer: four from effects of distant metastases and 1 from progressive local disease. The 3-year local, regional, and overall survival rates were 87.1%, 92%, and 85.9%, respectively. All patients experienced some degree of acute and/or late toxicity. Moderate to severe late toxicities (grade 3 and 4) were observed in 17% of cases. This C-Boost radiotherapy regimen administers a higher biologically effective dose compared with conventional radiation schedules. The local control after C-Boost radiation seems high for patients with stage II nasopharyngeal carcinoma, thus justifies further investigation to confirm its efficacy. © 2007 Elsevier Ltd. All rights reserved.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.oraloncology.2007.09.005
dc.sourceScopus
dc.subjectAccelerated concomitant boost radiotherapy
dc.subjectNasopharyngeal cancer
dc.subjectRadiation therapy
dc.typeArticle
dc.contributor.departmentOTOLARYNGOLOGY
dc.description.doi10.1016/j.oraloncology.2007.09.005
dc.description.sourcetitleOral Oncology
dc.description.volume44
dc.description.issue7
dc.description.page703-709
dc.identifier.isiut000258056200013
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

2
checked on Jun 11, 2019

WEB OF SCIENCETM
Citations

2
checked on Jun 11, 2019

Page view(s)

188
checked on May 25, 2019

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.